Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
Date:12/8/2011

SEATTLE, Dec. 9, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (Nasdaq and MTA:CTIC) (the "Company") today announced that it has entered into an agreement to sell, subject to customary closing conditions, $20 million of shares of its Series 14 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to two institutional investors.  Each share of Series 14 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 870 shares of common stock at a conversion price of $1.15 per share of common stock, for a total of approximately 17,391,304 shares of common stock.

In connection with the offering, the investors received warrants to purchase up to 6,956,522 shares of common stock. The warrants have an exercise price of $1.45 per warrant share, for total potential additional proceeds to the Company of approximately $10.1 million upon exercise of the warrants for cash. The warrants are exercisable beginning six months and one day after the date of issuance and expire five years and one day after the date of issuance.

The Company intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital. The Company may also use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products. The Company has recently engaged in limited discussions with third parties regarding such investments or acquisitions, but has no current agreements or commitments with respect to any investment or acquisitions.

Shares of the Series 14 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO Investor Forum
2. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
3. Reed V. Tuckson, M.D., Executive Vice President and Chief of Medical Affairs at UnitedHealth Group, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO
5. Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation
6. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
7. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
8. Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
9. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants
10. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
11. Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... Oxybutynin Hydrochloride Industry, 2009-2019 is a professional ... Chinese Oxybutynin Hydrochloride industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Oxybutynin Hydrochloride listing their ...
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... 19, 2014 According to ... (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), ... technologies - Global Forecast to 2019" published by ... reach $19,786.3 Million by 2019 from $14,240.0 Million ... 2014 to 2019. Browse 74 market ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... , , VIENNA, Va. , ... , a late-stage oncology company and a developer of vaccines ... the appointment of Todd S. Burkhart as Vice ...  Mr. Burkhart has over 30 years of experience in the ...
... , Jan. 14 Span-America Medical Systems, Inc. ... its conference call on Friday, January 29, 2010 , ... be released after the regular close of trading the preceding ... be available online at www.spanamerica.com under investor relations ...
Cached Medicine Technology:CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations 2Span-America Announces First Quarter Conference Call On The Internet 2
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- The U.S. Food ... Trulicity, on Thursday. Trulicity is part of a class of ... adults with type 2 diabetes. "Trulicity is a ... to existing treatment regimens to control blood sugar levels in ... deputy director of the FDA,s Office of Drug Evaluation II, ...
(Date:9/19/2014)... cells to treat and cure disease is a ... hindered by the inability of doctors and scientists to ... cells in patients without resorting to invasive procedures, like ... in the online journal Magnetic Resonance in Medicine ... School of Medicine, University of Pittsburgh and elsewhere describe ...
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... -- More states are passing legislation permitting or requiring ... any child having a severe allergic reaction. Epinephrine ... reaction that can lead to throat swelling, breathing difficulties, ... In people with severe allergies to certain ... or certain drugs, anaphylaxis can occur within moments of ...
(Date:9/19/2014)... September 19, 2014 Top 10 ... recently announced that HostGator.com, GoDaddy and Bluehost are ... These companies are the most recommended suppliers for ... Europe to buy high quality Linux hosting (including ... ) is one of many top hosting companies ...
Breaking Medicine News(10 mins):Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:A better way to track emerging cell therapies using MRIs 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2
... Inc's brand cleansing solution has been linked to a severe ... Optometry doctors in the U.S have urged contact lens wearers ... Bausch & Lomb Inc. has stopped shipping ... following warnings from the U.S. Food and Drug Administration (FDA) ...
... than 1lb 6oz. He was so weak that he needed life ... he lived and grew stronger. //Even his mother Donna Morgan who ... be given blood transfusions to recover. ,Now the mother ... helped them, they are launching a campaign to fill the worryingly ...
... from far but far from good! A city that has ... life// , might not be promoting feelings of well-being in ... happen to be a highly distressed lot compared to the ... cause of distress, opining that nearly one out of seven ...
... Ontario plans to revamp the drug system. Health Minister ... to improve the drug program//. He also said that ... drug system transparent and sustainable. They will also speed ... voices are heard. The taxpayers have not received fair ...
... in the April issue of IJCP, the International Journal ... of cases of invasive// pneumococcal diseases (IPD) like meningitis ... still only vaccinate selected at-risk groups against IPD. ... vaccination of infants and young children reduces their risk ...
... obesity is due at least in part to an ... when to stop eating, and a protein more recently// ... protein (CRP) not only binds to leptin but its ... The results may help explain why obese people have ...
Cached Medicine News:Health News:Promotion of Pneumococcal Vaccine Slow in Europe 2Health News:Promotion of Pneumococcal Vaccine Slow in Europe 3Health News:Researchers Identify The Cause To Obesity 2Health News:Researchers Identify The Cause To Obesity 3
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... Clopidogrel Assay measures changes in platelet ... Clopidogrel (Plavix). It uses a specific ... clopidogrel inhibits. The assay has not ... the assay is available for Research ...
Medicine Products: